Patents by Inventor Stephen Safe

Stephen Safe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12264150
    Abstract: NR4A1 ligands, pharmaceutical compositions including the NR4A1 ligands, and related methods of use are described. Methods of treating a disease or condition in an individual treatable by modulation of NR4A1 activity, comprising administering to the individual a therapeutically effective amount of a compound or a pharmaceutical composition described herein.
    Type: Grant
    Filed: October 26, 2021
    Date of Patent: April 1, 2025
    Assignee: The Texas A&M University System
    Inventor: Stephen Safe
  • Publication number: 20230113363
    Abstract: Methods of treating endometriosis through modulation of Nuclear Receptor Subfamily 4 Group A Member 1 (NR4A1) activity including administration of an NR4A1 ligand to an individual in need thereof are described. In an embodiment, the compounds include methylene substituted diindolylmethanes.
    Type: Application
    Filed: February 24, 2021
    Publication date: April 13, 2023
    Applicant: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Stephen Safe, Kumaravel Mohankumar
  • Publication number: 20220332703
    Abstract: NR4A1 ligands, pharmaceutical compositions including the NR4A1 ligands, and related methods of use are described. Methods of treating a disease or condition in an individual treatable by modulation of NR4A1 activity, comprising administering to the individual a therapeutically effective amount of a compound or a pharmaceutical composition described herein.
    Type: Application
    Filed: October 26, 2021
    Publication date: October 20, 2022
    Applicant: The Texas A&M University System
    Inventor: Stephen SAFE
  • Publication number: 20220265606
    Abstract: In an embodiment, the present disclosure pertains to a method of treating a disease by induction of activity in cells. Generally, the method includes administering a bis-indole-derived compound to a subject in need thereof. In some embodiments, the method further includes binding, by the bis-indole-derived compound, to at least one of nuclear receptor 4A1 (NR4A1) and nuclear receptor 4A2 (NR4A2). In another embodiment, the present disclosure pertains to a compound for treating a disease by induction of activity in cells. Generally, the compound includes a bis-indole-derived compound. In some embodiments, the bis-indole-derived compound binds to at least one of NR4A1 and NR4A2.
    Type: Application
    Filed: July 31, 2020
    Publication date: August 25, 2022
    Inventors: Stephen Safe, Xi Li, Keshav Karki
  • Publication number: 20200239448
    Abstract: NR4A1 ligands, pharmaceutical compositions including the NR4A1 ligands, and related methods of use are described. Methods of treating a disease or condition in an individual treatable by modulation of NR4A1 activity, comprising administering to the individual a therapeutically effective amount of a compound or a pharmaceutical composition described herein.
    Type: Application
    Filed: August 9, 2018
    Publication date: July 30, 2020
    Inventor: Stephen SAFE
  • Publication number: 20160303081
    Abstract: The present disclosure provides compositions and methods for inhibiting ?1-integrin expression and functionality, and for addressing any condition characterized by increased ?1-integrin levels, through inhibition of NR4A1 (TR3) in the cell.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Applicant: The Texas A&M University System
    Inventors: Stephen Safe, Syng-Ook Lee
  • Patent number: 8957042
    Abstract: Provided herein are methods directed to modulating the pro-oncogenic effects of noncoding RNAs (ncRNAs) through their interactions with specificity protein transcription factors (SpTFs). In one aspect, the disclosure provides a method of inhibiting growth of a cell, such as a transformed or cancer cell, characterized by overexpression of at least one specificity protein (Sp)-regulated ncRNA and expression of at least one Sp transcription factor (SpTF), the method comprising contacting the cell with an effective amount of an SpTF agent. In some embodiments, the ncRNA is a long noncoding RNA (lncRNA). In some embodiments, the ncRNA is a microRNA (miR). Also provided are methods of treating a cell proliferative disease, predicting the response of a subject to SpTF agent-based treatment, and monitoring the efficacy of a SpTF agent-based treatment in a subject.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: February 17, 2015
    Assignee: The Texas A&M University System
    Inventors: Stephen Safe, KyoungHyun Kim
  • Patent number: 8580843
    Abstract: Presented herein are diindolylmethane derivative compounds useful for the prevention and or treatment of neurological conditions, including neurological conditions related to neuroinflammation. One such neurological condition is Parkinson's disease.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: November 12, 2013
    Assignees: Colorado State University Research Foundation, The Texas A&M University System
    Inventors: Ronald B. Tjalkens, Stephen Safe
  • Publication number: 20130267575
    Abstract: Provided herein are methods directed to modulating the pro-oncogenic effects of noncoding RNAs (ncRNAs) through their interactions with specificity protein transcription factors (SpTFs). In one aspect, the disclosure provides a method of inhibiting growth of a cell, such as a transformed or cancer cell, characterized by overexpression of at least one specificity protein (Sp)-regulated ncRNA and expression of at least one Sp transcription factor (SpTF), the method comprising contacting the cell with an effective amount of an SpTF agent. In some embodiments, the ncRNA is a long noncoding RNA (lncRNA). In some embodiments, the ncRNA is a microRNA (miR). Also provided are methods of treating a cell proliferative disease, predicting the response of a subject to SpTF agent-based treatment, and monitoring the efficacy of a SpTF agent-based treatment in a subject.
    Type: Application
    Filed: March 7, 2013
    Publication date: October 10, 2013
    Applicant: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Stephen Safe, KyoungHyun Kim
  • Publication number: 20070259829
    Abstract: The present invention demonstrates that chemical-induced degradation of Sp proteins by a specific sub-class of NSAIDs inhibited cancer cell growth, angiogenesis and metastasis of cancer cells. The inhibitory effects of these compounds were demonstrated in vitro and in vivo. Hence, the results discussed herein indicate that these compounds can be used to inhibit cell growth, angiogenesis and metastasis in cancers such as pancreatic, breast, prostate, colon, bladder and ovarian cancers.
    Type: Application
    Filed: March 26, 2007
    Publication date: November 8, 2007
    Inventors: Maen Abdelrahim, Stephen Safe
  • Publication number: 20060084694
    Abstract: The present invention provides a method for inducing ligand-dependant Nur77 activation in a cell by contacting the cell with an effective dose of an agonist of Nur77. Also provided is a method for treating a mammal having a disease affected by modulation of Nur77 activity as well as a method for inducing apoptosis in a cell. The Nur77 agonists are preferably diindolylmethanes, and more preferably, methlylene-substituted diindolylmethanes. A representative example of the Nur77 agonists is a 1,1-bis (3?-indolyl)-1-(p-substituted phenyl) methane.
    Type: Application
    Filed: August 23, 2005
    Publication date: April 20, 2006
    Inventors: Stephen Safe, Sudhakar Chintharlapalli
  • Publication number: 20060079568
    Abstract: Diindolylmethane analogs such as 1,1-bis(3?-indolyl)-1-(p-substituted phenyl)methanes can be used to treat atherosclerosis and other vascular disease states. The analogs have been shown to display antiinflammatory effects in endothelial cells, suggesting their clinical applicability.
    Type: Application
    Filed: May 20, 2005
    Publication date: April 13, 2006
    Applicant: The Texas A&M University System
    Inventors: Stephen Safe, Ismael Samudio, Paolo Calabro, Edward Yeh
  • Publication number: 20050143450
    Abstract: The present invention is directed to a method of modulating a prostate neoplasm by administering an alkyl-substituted PCDF.
    Type: Application
    Filed: November 22, 2004
    Publication date: June 30, 2005
    Applicant: Texas A&M University System
    Inventor: Stephen Safe